Mitomycin C in the treatment of gastrointestinal tumours: recent data and perspectives.
Mitomycin C (MMC) is among the most effective anticancer drugs used for the treatment of a broad variety of tumours. This review summarises results of MMC-based chemotherapy in gastrointestinal tumours with special focus on current treatment options in gastric, pancreatic, biliary tract, colorectal, and anal cancer. In addition, these new developments are critically discussed with special attention to their potential clinical relevance.
Hofheinz
Ralf-Dieter
RD
Onkologisches Zentrum, III. Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Germany. ralf.hofheinz@med3.ma.uni-heidelberg.de
Beyer
Ulrich
U
Al-Batran
Salah-Eddin
SE
Hartmann
Jörg Thomas
JT
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D002986:Clinical Trials as Topic / Q000639:trends*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D016685:Mitomycin